Engineered heart tissue: high throughput platform for dissection of complex diseases.
ABSTRACT The polygenic nature of resistance/sensitivity of the heart to ischemia is generally accepted. Unfortunately, little is known about gene(s) involved in response to this insult. The goal of present study is to introduce new tool, engineered heart tissue (EHT), for accelerating positional cloning and for providing novel functional assays.
- SourceAvailable from: Christer Wingren[Show abstract] [Hide abstract]
ABSTRACT: Antibody-based microarrays are among the novel classes of rapidly evolving proteomic technologies that holds great promise in biomedicine. Miniaturized microarrays (< 1 cm2) can be printed with thousands of individual antibodies carrying the desired specificities, and with biological sample (e.g., an entire proteome) added, virtually any specifically bound analytes can be detected. While consuming only minute amounts (< microL scale) of reagents, ultra- sensitive assays (zeptomol range) can readily be performed in a highly multiplexed manner. The microarray patterns generated can then be transformed into proteomic maps, or detailed molecular fingerprints, revealing the composition of the proteome. Thus, protein expression profiling and global proteome analysis using this tool will offer new opportunities for drug target and biomarker discovery, disease diagnostics, and insights into disease biology. Adopting the antibody microarray technology platform, several biomedical applications, ranging from focused assays to proteome-scale analysis will be rapidly emerging in the coming years. This review will discuss the current status of the antibody microarray technology focusing on recent technological advances and key issues in the process of evolving the methodology into a high-performing proteomic research tool.Omics A Journal of Integrative Biology 09/2006; 10(3):411-27. DOI:10.1089/omi.2006.10.411 · 2.73 Impact Factor